Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, Michael Weiss, chief executive officer of TG Therapeutics, discussed ublituximab (Briumvi), a recently approved anti-CD20 therapy for relapsing multiple sclerosis, and the advantages it brings to patients. Specifically, he talked about the Department of Veteran Affairs' decision to award national contract to ublituximab as the preferred anti-CD20 for this patient population, and how this facilitates greater access to the treatment. In addition, he discussed how the knowledge profile of the agent has grown over time, as well as the additional efforts to gain a better understanding of its efficacy and safety. Furthermore, he spoke on the differences between ublituximab and other approved agents, and why it may be more applicable to certain patients.  Looking for more multiple sclerosis discussion? Check out the NeurologyLive® Multiple sclerosis clinical focus page. Episode Breakdown: 1:05 – Significance of ublituximab awarded national contract as preferred anti-CD20 for relapsing MS 3:30 – Advantages and differences of ublituximab vs approved therapies for MS 11:40 – Neurology News Minute 14:30 – Growing knowledge profile of ublituximab over the years 19:05 – Future plans of ubtlituximab; long-term goals of the therapy The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

Eli Lilly Announces Date for Donanemab FDA AdComm Hearing

Patient Death Reported in Phase 2 DAYLIGHT Study of Pfizer’s Gene Therapy for Duchenne

ALS Candidate PrimeC Shows Greater Treatment Effect in High-Risk ALS